INS and Hypoglycemia: Dipeptidyl peptidase 4 (DPP-4) inhibitors increase insulin secretion and suppress glucagon secretion in a glucose-dependent manner through enhancement of the effect of endogenous incretin, thereby improving postprandial glycemic excursion without increasing the risk of hypoglycemia.